Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market ...
FDA accepted NDA for zidesamtinib for the treatment of TKI pre-treated patients with advanced ROS1-positive NSCLC; PDUFA target action date of September ...
From new imaging and targeted therapies to patient journeys, 2025 highlighted key advances and personal stories in lung ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...
The final, formatted version of the article will be published soon. Background: High-grade endometrial stromal sarcoma (HG-ESS) is a very rare and aggressive uterine malignancy. Although recurrent ...
AstraZeneca has fronted $100 million to head deeper into the KRAS space, securing the rights to a clinical-stage, multitarget asset from China’s Jacobio Pharma. U.K.-based AstraZeneca has scored the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback